ZLDPF
Zealand Pharma A/S
Price Chart
Latest Quote
$49.75
+1.15 (+2.37%)
Current Price
| Previous Close | $48.60 |
| Open | $50.35 |
| Day High | $50.35 |
| Day Low | $49.75 |
| Volume | 200 |
Stock Information
Note: Financial values converted from DKK to USD
| Shares Outstanding | 70.08M |
| Total Debt | $63.83M |
| Cash Equivalents | $2.23B |
| Revenue | $1.42B |
| Net Income | $986.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.49B |
| P/E Ratio | 3.58 |
| EPS (TTM) | $13.90 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-10.54B |
| Sales | $1.42B |
| Income | $986.20M |
| Book/sh | $32.52 |
| Cash/sh | $206.46 |
| Employees | 544 |
Financial Ratios
| Quick Ratio | 36.40 |
| Current Ratio | 37.17 |
| Debt/Eq | 2.86 |
Returns & Margins
| ROA | 34.72% |
| ROE | 56.16% |
| Gross Margin | 99.99% |
| Operating Margin | -1585.29% |
| Profit Margin | 69.21% |
Ownership
| Insider Ownership | 0.53% |
| Institutional Ownership | 51.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -42.89 |
| P/S | 0.38 |
| P/B | 1.53 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $49.84 |
| SMA50 | $48.07 |
| SMA200 | $63.06 |
| RSI | 56.47 |
| ATR | 0.6461 |
| Shares Float | 56.67M |
| Volatility | 0.59 |
| Rel Volume | 0.95 |
Performance History
| Week | +2.07% |
| Month | +1.98% |
| Quarter | +25.00% |
| 6 Months | -35.52% |
| YTD | -31.10% |
| Year | -30.13% |
| 3 Years | +30.07% |
| 5 Years | +52.61% |
| 10 Years | +153.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $49.75 | 200 |
| 2026-06-04 | $49.02 | 0 |
| 2026-06-03 | $49.02 | 0 |
| 2026-06-02 | $49.02 | 0 |
| 2026-06-01 | $49.02 | 1,887 |
| 2026-05-29 | $48.74 | 0 |
| 2026-05-28 | $48.74 | 218 |
| 2026-05-27 | $50.82 | 154 |
| 2026-05-26 | $50.26 | 0 |
| 2026-05-22 | $50.26 | 200 |
| 2026-05-21 | $48.89 | 0 |
| 2026-05-20 | $48.89 | 200 |
| 2026-05-19 | $48.12 | 0 |
| 2026-05-18 | $48.12 | 400 |
| 2026-05-15 | $48.90 | 0 |
| 2026-05-14 | $48.90 | 0 |
| 2026-05-13 | $48.90 | 179 |
| 2026-05-12 | $54.00 | 0 |
| 2026-05-11 | $54.00 | 100 |
| 2026-05-08 | $53.52 | 671 |
| 2026-05-07 | $54.28 | 1,192 |
| 2026-05-06 | $48.78 | 100 |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
đ° Latest News
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
Zacks âĸ 2026-05-12T13:40:03Z
Zealand Pharma Obesity Trials Shape Future Revenue Potential And Partner Dependence
Simply Wall St. âĸ 2026-05-12T02:07:55Z
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T11:10:04Z
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
Zacks âĸ 2026-05-05T22:05:11Z
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-04-30T12:30:03Z
Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Positive Survodutide Phase 3 Obesity Trial Results
Simply Wall St. âĸ 2026-04-29T11:06:12Z
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
BioPharma Dive âĸ 2026-04-28T11:44:00Z
Assessing Zealand Pharma (CPSE:ZEAL) Valuation As New Cambridge Research Hub Expands AI Drug Discovery
Simply Wall St. âĸ 2026-03-25T22:05:03Z
Zealand Pharma Announces Share Capital Increase
MT Newswires âĸ 2026-03-19T21:22:01ZRoche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story
Simply Wall St. âĸ 2026-03-09T13:08:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,874,000 | $19,174,000 | $0 | $10,970,000 |
| Cost Of Revenue | $7,874,000 | $19,174,000 | $0 | $10,970,000 |
| Total Revenue | $62,691,000 | $342,788,000 | $103,986,000 | $108,546,000 |
| Operating Revenue | $62,691,000 | $342,788,000 | $103,986,000 | $108,546,000 |
| Expenses | ||||
| Interest Expense | $34,047,000 | $25,831,000 | $56,455,000 | $4,091,000 |
| Total Expenses | $1,331,762,000 | $920,005,000 | $920,585,000 | $890,690,000 |
| Net Non Operating Interest Income Expense | $128,739,000 | $16,343,000 | $-48,681,000 | $-7,520,000 |
| Total Other Finance Cost | $6,853,000 | $3,150,000 | $-1,232,000 | $3,473,000 |
| Interest Expense Non Operating | $34,047,000 | $25,831,000 | $56,455,000 | $4,091,000 |
| Operating Expense | $1,323,888,000 | $900,831,000 | $920,585,000 | $879,720,000 |
| Selling And Marketing Expense | $68,686,000 | $16,052,000 | $32,298,000 | $62,600,000 |
| General And Administrative Expense | $160,515,000 | $73,797,000 | $274,243,000 | $235,609,000 |
| Other Income Expense | - | - | - | $30,777,000 |
| Other Operating Expenses | - | - | - | $-759,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,078,828,000 | $-703,739,000 | $-965,610,000 | $-754,938,000 |
| Net Interest Income | $128,739,000 | $16,343,000 | $-48,681,000 | $-7,520,000 |
| Interest Income | $169,639,000 | $45,324,000 | $6,542,000 | $44,000 |
| Normalized Income | $-1,117,261,518 | $-566,455,963 | $-834,122,710 | $-749,220,906 |
| Net Income From Continuing And Discontinued Operation | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Total Operating Income As Reported | $-1,272,207,000 | $-572,238,000 | $-837,153,000 | $-784,317,000 |
| Net Income Common Stockholders | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Net Income | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Net Income Including Noncontrolling Interests | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Net Income Continuous Operations | $-1,078,828,000 | $-703,739,000 | $-965,610,000 | $-754,938,000 |
| Pretax Income | $-1,083,445,000 | $-708,865,000 | $-972,041,000 | $-758,887,000 |
| Special Income Charges | $-3,136,000 | $-130,609,000 | $-143,137,000 | $-2,173,000 |
| Interest Income Non Operating | $169,639,000 | $45,324,000 | $6,542,000 | $44,000 |
| Operating Income | $-1,269,071,000 | $-577,217,000 | $-816,599,000 | $-782,144,000 |
| Depreciation And Amortization In Income Statement | $6,255,000 | $6,369,000 | - | $4,390,000 |
| Depreciation Income Statement | $6,255,000 | $6,369,000 | - | $4,390,000 |
| Gross Profit | $54,817,000 | $323,614,000 | $103,986,000 | $97,576,000 |
| Net Income Discontinuous Operations | - | $0 | $-236,525,000 | $-263,211,000 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $4,390,000 |
| Per Share | ||||
| Diluted EPS | $-16.24 | $-12.44 | $-26.02 | $-23.75 |
| Basic EPS | $-16.24 | $-12.44 | $-26.02 | $-23.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $164,482 | $-999,963 | $-875,710 | $-29,906 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,062,149,000 | $-519,665,000 | $-665,262,000 | $-706,103,000 |
| Total Unusual Items | $38,598,000 | $-138,283,000 | $-132,363,000 | $-5,747,000 |
| Total Unusual Items Excluding Goodwill | $38,598,000 | $-138,283,000 | $-132,363,000 | $-5,747,000 |
| Reconciled Depreciation | $25,847,000 | $25,086,000 | $117,961,000 | $42,946,000 |
| EBITDA (Bullshit earnings) | $-1,023,551,000 | $-657,948,000 | $-797,625,000 | $-711,850,000 |
| EBIT | $-1,049,398,000 | $-683,034,000 | $-915,586,000 | $-754,796,000 |
| Diluted Average Shares | $66,434,266 | $56,588,587 | $46,200,152 | $42,869,395 |
| Basic Average Shares | $66,434,266 | $56,588,587 | $46,200,152 | $42,869,395 |
| Diluted NI Availto Com Stockholders | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $-4,617,000 | $-5,126,000 | $-6,431,000 | $-3,949,000 |
| Other Special Charges | $3,136,000 | $135,588,000 | $124,039,000 | $2,173,000 |
| Write Off | $0 | $-15,979,000 | $0 | - |
| Impairment Of Capital Assets | $0 | $11,000,000 | $0 | - |
| Research And Development | $919,866,000 | $684,902,000 | $614,044,000 | $581,511,000 |
| Selling General And Administration | $229,201,000 | $89,849,000 | $306,541,000 | $298,209,000 |
| Restructuring And Mergern Acquisition | - | $0 | $19,098,000 | $0 |
| Gain On Sale Of Ppe | - | - | - | $-2,173,000 |
| Gain On Sale Of Security | - | - | - | $32,950,000 |
| Other Gand A | - | - | - | $128,967,000 |
| Salaries And Wages | - | - | - | $127,630,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,604,122,000 | $1,580,584,000 | $815,911,000 | $874,013,000 |
| Total Assets | $9,505,600,000 | $1,979,993,000 | $1,539,806,000 | $2,067,629,000 |
| Total Non Current Assets | $977,896,000 | $200,205,000 | $223,454,000 | $346,033,000 |
| Non Current Deferred Taxes Assets | $985,000 | $925,000 | $2,017,000 | $13,525,000 |
| Investmentin Financial Assets | $819,632,000 | $21,379,000 | $6,901,000 | $0 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $0 | $14,004,000 | - | - |
| Goodwill And Other Intangible Assets | $12,620,000 | $12,255,000 | $0 | $53,790,000 |
| Other Intangible Assets | $12,620,000 | $12,255,000 | - | $53,790,000 |
| Current Assets | $8,527,704,000 | $1,779,788,000 | $1,316,352,000 | $1,721,596,000 |
| Prepaid Assets | $106,390,000 | - | - | $64,626,000 |
| Inventory | $10,698,000 | $7,935,000 | $1,286,000 | $118,436,000 |
| Other Receivables | $138,475,000 | $24,556,000 | - | $5,120,000 |
| Taxes Receivable | $45,632,000 | $16,437,000 | $21,599,000 | $21,562,000 |
| Accounts Receivable | $499,000 | $97,803,000 | $115,622,000 | $153,453,000 |
| Cash Cash Equivalents And Short Term Investments | $8,226,010,000 | $1,633,057,000 | $1,177,845,000 | $1,428,145,000 |
| Cash And Cash Equivalents | $480,303,000 | $449,311,000 | $1,069,234,000 | $1,129,103,000 |
| Non Current Prepaid Assets | - | - | - | $29,095,000 |
| Non Current Deferred Assets | - | - | - | $13,525,000 |
| Non Current Accounts Receivable | - | - | - | $1,268,000 |
| Receivables | - | - | - | $110,389,000 |
| Debt | ||||
| Total Debt | $391,756,000 | $119,230,000 | $443,472,000 | $787,429,000 |
| Long Term Debt And Capital Lease Obligation | $375,720,000 | $102,575,000 | $428,743,000 | $772,532,000 |
| Long Term Debt | $285,332,000 | $0 | $320,743,000 | $647,906,000 |
| Current Debt And Capital Lease Obligation | $16,036,000 | $16,655,000 | $14,729,000 | $14,897,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $888,858,000 | $387,154,000 | $723,895,000 | $1,139,826,000 |
| Total Non Current Liabilities Net Minority Interest | $485,385,000 | $102,575,000 | $528,404,000 | $805,509,000 |
| Derivative Product Liabilities | $109,665,000 | $0 | $80,603,000 | - |
| Current Liabilities | $403,473,000 | $284,579,000 | $195,491,000 | $334,317,000 |
| Payables | $220,886,000 | $182,730,000 | $180,762,000 | $266,387,000 |
| Other Payable | $39,607,000 | $91,123,000 | - | - |
| Accounts Payable | $181,279,000 | $91,607,000 | $180,762,000 | $266,387,000 |
| Tradeand Other Payables Non Current | - | - | $19,058,000 | $18,426,000 |
| Other Non Current Liabilities | - | - | - | $18,426,000 |
| Non Current Deferred Liabilities | - | - | - | $14,551,000 |
| Other Current Liabilities | - | - | - | $201,829,000 |
| Current Deferred Liabilities | - | - | - | $53,033,000 |
| Payables And Accrued Expenses | - | - | - | $64,558,000 |
| Total Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $8,616,742,000 | $1,592,839,000 | $815,911,000 | $927,803,000 |
| Total Equity Gross Minority Interest | $8,616,742,000 | $1,592,839,000 | $815,911,000 | $927,803,000 |
| Stockholders Equity | $8,616,742,000 | $1,592,839,000 | $815,911,000 | $927,803,000 |
| Retained Earnings | $-6,157,441,000 | $-4,894,841,000 | $-4,171,640,000 | $-3,308,402,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $14,155,000 |
| Other | ||||
| Treasury Shares Number | $373,501 | $373,134 | $230,063 | $418,247 |
| Ordinary Shares Number | $70,650,370 | $58,378,018 | $51,472,035 | $43,215,895 |
| Share Issued | $71,023,871 | $58,751,152 | $51,702,098 | $43,634,142 |
| Tangible Book Value | $8,604,122,000 | $1,580,584,000 | $815,911,000 | $874,013,000 |
| Invested Capital | $8,902,074,000 | $1,592,839,000 | $1,136,654,000 | $1,575,709,000 |
| Working Capital | $8,124,231,000 | $1,495,209,000 | $1,120,861,000 | $1,387,279,000 |
| Capital Lease Obligations | $106,424,000 | $119,230,000 | $122,729,000 | $139,523,000 |
| Total Capitalization | $8,902,074,000 | $1,592,839,000 | $1,136,654,000 | $1,575,709,000 |
| Additional Paid In Capital | $14,680,771,000 | $6,406,225,000 | $4,921,232,000 | $4,250,306,000 |
| Capital Stock | $71,024,000 | $58,751,000 | $51,702,000 | $43,634,000 |
| Common Stock | $71,024,000 | $58,751,000 | $51,702,000 | $43,634,000 |
| Long Term Capital Lease Obligation | $90,388,000 | $102,575,000 | $108,000,000 | $124,626,000 |
| Current Capital Lease Obligation | $16,036,000 | $16,655,000 | $14,729,000 | $14,897,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $92,987,000 | $51,730,000 | - | - |
| Available For Sale Securities | $819,632,000 | $7,375,000 | $6,901,000 | - |
| Net PPE | $125,247,000 | $149,852,000 | $165,488,000 | $221,449,000 |
| Accumulated Depreciation | $-77,723,000 | $-70,431,000 | $-71,360,000 | $-68,890,000 |
| Gross PPE | $202,970,000 | $220,283,000 | $236,848,000 | $221,449,000 |
| Construction In Progress | $0 | $0 | $870,000 | $12,112,000 |
| Machinery Furniture Equipment | $85,959,000 | $80,492,000 | $84,406,000 | $108,255,000 |
| Buildings And Improvements | $117,011,000 | $139,791,000 | $151,572,000 | $169,971,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $10,698,000 | $7,935,000 | $1,286,000 | $35,816,000 |
| Other Short Term Investments | $7,745,707,000 | $1,183,746,000 | $108,611,000 | $299,042,000 |
| Other Investments | - | $14,004,000 | $30,943,000 | $26,907,000 |
| Non Current Deferred Revenue | - | - | $0 | $14,551,000 |
| Finished Goods | - | - | $0 | $53,032,000 |
| Work In Process | - | - | $0 | $29,588,000 |
| Foreign Currency Translation Adjustments | - | - | - | $14,155,000 |
| Treasury Stock | - | - | - | $71,890,000 |
| Current Deferred Revenue | - | - | - | $53,033,000 |
| Investments And Advances | - | - | - | $26,907,000 |
| Other Properties | - | - | - | $221,449,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-943,964,000 | $-449,417,000 | $-954,021,000 | $-1,234,104,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-930,816,000 | $-425,668,000 | $-942,311,000 | $-1,211,971,000 |
| Cash Flow From Continuing Operating Activities | - | - | - | $-1,211,971,000 |
| Operating Gains Losses | - | - | - | $-66,246,000 |
| Investing Activities | ||||
| Capital Expenditure | $-13,148,000 | $-23,749,000 | $-11,710,000 | $-22,133,000 |
| Investing Cash Flow | $-7,332,915,000 | $-1,094,033,000 | $281,259,000 | $-18,121,000 |
| Cash Flow From Continuing Investing Activities | - | - | - | $-18,121,000 |
| Net Other Investing Changes | - | - | - | $4,012,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-351,834,000 | $-41,600,000 | $0 | $-28,590,000 |
| Issuance Of Capital Stock | $8,523,479,000 | $1,563,950,000 | $1,084,661,000 | $775,045,000 |
| Financing Cash Flow | $8,288,491,000 | $907,014,000 | $587,500,000 | $1,332,751,000 |
| Net Common Stock Issuance | $8,171,645,000 | $1,522,350,000 | $1,084,661,000 | $746,455,000 |
| Common Stock Issuance | $8,523,479,000 | $1,563,950,000 | $1,084,661,000 | $775,045,000 |
| Cash Flow From Continuing Financing Activities | - | - | - | $1,332,751,000 |
| Net Other Financing Charges | - | - | - | $-46,895,000 |
| Dividends Received Cfi | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-525,764,000 | $-436,088,000 | $0 |
| Issuance Of Debt | $369,867,000 | $0 | $0 | $647,906,000 |
| End Cash Position | $480,303,000 | $449,311,000 | $1,069,234,000 | $1,129,103,000 |
| Beginning Cash Position | $449,311,000 | $1,069,234,000 | $1,129,103,000 | $960,221,000 |
| Effect Of Exchange Rate Changes | $6,232,000 | $-7,236,000 | $13,683,000 | $66,223,000 |
| Changes In Cash | $24,760,000 | $-612,687,000 | $-73,552,000 | $102,659,000 |
| Common Stock Payments | $-351,834,000 | $-41,600,000 | $0 | $-28,590,000 |
| Net Issuance Payments Of Debt | $369,867,000 | $-525,764,000 | $-436,088,000 | $647,906,000 |
| Net Long Term Debt Issuance | $369,867,000 | $-525,764,000 | $-436,088,000 | $647,906,000 |
| Long Term Debt Payments | $0 | $-525,764,000 | $-436,088,000 | $0 |
| Long Term Debt Issuance | $369,867,000 | $0 | $0 | $647,906,000 |
| Net Investment Purchase And Sale | $-7,319,767,000 | $-1,070,284,000 | $186,583,000 | $0 |
| Sale Of Investment | $4,137,897,000 | $1,089,547,000 | $887,060,000 | $0 |
| Purchase Of Investment | $-11,457,664,000 | $-2,159,831,000 | $-700,477,000 | $0 |
| Net Intangibles Purchase And Sale | $-3,095,000 | $-12,508,000 | $0 | $0 |
| Purchase Of Intangibles | $-3,095,000 | $-12,508,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-10,053,000 | $-11,241,000 | $-11,710,000 | $-22,133,000 |
| Purchase Of PPE | $-10,053,000 | $-11,241,000 | $-11,710,000 | $-22,133,000 |
| Taxes Refund Paid | $11,155,000 | $11,300,000 | $9,277,000 | $-41,631,000 |
| Interest Received Cfo | $119,010,000 | $37,887,000 | $5,178,000 | $0 |
| Interest Paid Cfo | $-24,031,000 | $-25,252,000 | $-34,124,000 | $-3,296,000 |
| Change In Working Capital | $122,379,000 | $52,103,000 | $10,161,000 | $-166,325,000 |
| Change In Other Current Liabilities | $110,105,000 | $-7,002,000 | $-80,301,000 | - |
| Change In Payable | $89,915,000 | $39,837,000 | $21,550,000 | $-49,059,000 |
| Change In Prepaid Assets | $-71,426,000 | $28,534,000 | $17,581,000 | - |
| Change In Inventory | $-2,762,000 | $9,339,000 | $18,221,000 | $-52,772,000 |
| Change In Receivables | $-3,453,000 | $-18,605,000 | $33,110,000 | $-64,494,000 |
| Other Non Cash Items | $-188,763,000 | $136,626,000 | $65,973,000 | $-8,887,000 |
| Stock Based Compensation | $87,032,000 | $61,426,000 | $52,286,000 | $53,504,000 |
| Deferred Tax | $-4,617,000 | $-5,125,000 | $9,893,000 | $-1,190,000 |
| Depreciation And Amortization | $25,847,000 | $25,086,000 | $117,961,000 | $42,946,000 |
| Depreciation | $25,847,000 | $25,086,000 | $117,961,000 | $42,946,000 |
| Net Income From Continuing Operations | $-1,078,828,000 | $-703,739,000 | $-1,202,135,000 | $-1,018,149,000 |
| Other Cash Adjustment Outside Changein Cash | - | $1,000 | - | - |
| Net Business Purchase And Sale | - | $0 | $106,386,000 | $0 |
| Sale Of Business | - | $0 | $106,386,000 | $0 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $23,219,000 | $-68,943,000 |
| Purchase Of Business | - | - | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $26,070,000 |
| Sale Of PPE | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $0 |
| Change In Payables And Accrued Expense | - | - | - | $-49,059,000 |
| Deferred Income Tax | - | - | - | $-1,190,000 |
| Depreciation Amortization Depletion | - | - | - | $40,249,000 |
| Gain Loss On Sale Of PPE | - | - | - | $2,697,000 |
Fetched: 2026-02-02